Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
atezolizumab + quaratusugene ozeplasmid
- Development stage
- Phase 2
- Lead developer
- Genprex
- Modality
- Gene Therapies, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Atezolizumab is a monoclonal antibody targeting PD-L1, used as an immune checkpoint inhibitor to enhance anti-tumor immune responses. Quaratusugene ozeplasmid is a gene therapy delivering a plasmid encoding the tumor suppressor gene TUSC2, which is often lost or reduced in small cell lung cancer. The combination of atezolizumab and quaratusugene ozeplasmid is being investigated as maintenance therapy for extensive-stage small cell lung cancer (ES-SCLC), with preclinical data suggesting enhanced tumor control compared to either agent alone[5][7][2]. The Acclaim-3 clinical trial evaluates this combination in patients who have not progressed after initial standard treatment with chemotherapy and atezolizumab[1][7][8].
- Brand names
- REQORSA + Tecentriq
- Other names
- quaratusugene ozeplasmid and atezolizumabREQORSA and atezolizumabREQORSA and Tecentriq
02
Targets
CD274 (Programmed cell death protein 1 ligand 1)TUSC2 (Tumor suppressor candidate 2)
Beyond the preview
Go deeper on atezolizumab + quaratusugene ozeplasmid.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on atezolizumab + quaratusugene ozeplasmid.